Sebia
Sebia is a global leader in specialized in vitro diagnostics, providing instruments and reagents for screening and monitoring diseases in oncology (Multiple Myeloma), diabetes, hemoglobinopathies, autoimmune, and infectious diseases. Following the acquisitions of ORGENTEC, Corgenix (2021), ZEUS Scientific (2022), and SciMedx (2024), Sebia expanded its autoimmune diagnostics portfolio. Its proprietary Anti-MCV autoantibody marker is widely used for diagnosing rheumatoid arthritis, particularly in early or seronegative cases, and is increasingly recognized for its potential in disease monitoring and prognosis.
